Aptahem AB Logo

Aptahem AB

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions. The company's research focuses on illnesses where coagulation, inflammation, and tissue damage are involved. Its lead candidate, Apta-1, is an aptamer currently in clinical development with sepsis as its primary indication. Aptahem aims to address the significant unmet medical need for effective treatments for sepsis and other severe inflammatory diseases, which currently rely only on supportive care. The company's proprietary technology leverages the unique multi-mechanistic profile of aptamers as a potential disruptive treatment.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Aptahem AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genmab Logo
Develops antibody therapeutics for cancer and serious diseases using proprietary technology.
Denmark GMAB
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
genOway Logo
Develops genetically engineered preclinical models for biopharma and academic research.
France ALGEN
GenSight Biologics S.A. Logo
Biopharma developing gene therapies for retinal neurodegenerative diseases and CNS disorders.
France SIGHT
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Guard Therapeutics International AB Logo
Clinical-stage biotech developing protein-based therapies for acute kidney injury.
Sweden GUARD
Gubra A/S Logo
Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.
Denmark GUBRA
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops novel therapies for life-threatening blood disorders, cancers, and autoimmune diseases.
United Kingdom HEMO
Herantis Pharma Oyj Logo
Clinical-stage biotech developing therapies for neurodegenerative disorders like Parkinson's.
Finland HRTIS